Omeros (OMER) Insider Diana Perkinson Buys 15,000 Shares

Diana Perkinson Acquires Omeros Stock

Diana Perkinson acquired 15,000 shares of Omeros Corporation OMER on June 18, 2026. This transaction adds to personal stakes within the leadership group at the clinical-stage biotech firm, catching the eye of market watchers monitoring insider activity.

Broad Leadership Buying Wave

Perkinson's trade was not an isolated event. On the exact same day, June 18, 2026, several other key figures at the firm also expanded their holdings by picking up 15,000 shares each. Thomas Cable, Demopulos Peter Md, Arnold Hanish, Thomas Bumol, Rajiv Shah, and Hood Leroy Md Phd all executed identical share acquisitions during this coordinated round of purchases.

Stock Valuation and Price Levels

Shares of Omeros Corporation trade on the NasdaqGM exchange, changing hands around $10.33. The stock moves within a 52-week range bounded by a low of $6.24 and a high of $21.24. The biotechnology company carries a market capitalization of roughly $1.36 billion and a price-to-earnings ratio of 15.40, alongside a forward P/E of 15.28.

Wall Street Analyst Updates

Financial firms continue to track the clinical-stage drug developer closely. On June 26, 2026, HC Wainwright & Co. maintained a buy rating while adjusting its price target to $33.00 from $40.00. Later, Cantor Fitzgerald upgraded the equity to an overweight rating on September 22, 2026, and subsequently reiterated that overweight stance with a $22.00 price target on October 14, 2026. The consensus recommendation from covering analysts stands at a buy.

Inside the Biotechnology Pipeline

Omeros Corporation operates out of Seattle, Washington, focusing on the discovery and development of small-molecule and protein therapeutics. Its pipeline targets orphan indications, immunologic conditions, and disorders involving the lectin pathway. Lead clinical candidates include treatments for hematopoietic stem-cell transplant-associated thrombotic microangiopathy, alongside early-stage programs addressing various central nervous system and immune-mediated ailments.

What to Watch at Omeros Corporation

Investors tracking Omeros will watch for further regulatory filings and updates regarding its clinical trials ahead of the next scheduled earnings report on November 12, 2026. Insider transactions reflect personal decisions by individual executives and board members and do not guarantee future stock performance.